The FDA‘s hasty rollout of artificial intelligence tools is raising serious concerns among agency staff, who report that the new agency-wide AI system is providing inaccurate information despite leadership’s enthusiasm. This tension highlights a growing divide between the Trump administration’s aggressive AI implementation goals and the practical realities of deploying reliable AI systems in regulatory contexts where precision and accuracy are paramount.
The big picture: The FDA has prematurely launched an agency-wide large language model called Elsa, despite staff concerns about accuracy and functionality.
- Commissioner Marty Makary proudly announced the rollout was “ahead of schedule and under budget,” emphasizing speed over performance.
- The system is being promoted to enhance everything from clinical protocol reviews to identifying inspection targets and summarizing adverse events.
Behind the claims: FDA staffers testing Elsa discovered significant problems with the tool’s reliability and accuracy.
- When questioned about FDA-approved products or public information, Elsa provided summaries that were either completely or partially incorrect.
- Employees told Stat news the tool was “rushed” and its capabilities were “overinflated” by officials, including those at the Department of Government Efficiency headed by Elon Musk.
Key details: The AI system is based on Anthropic’s Claude LLM and is being developed by consulting firm Deloitte.
- Deloitte has received $13.8 million since 2020 to develop the original database of FDA documents that forms Elsa’s training data.
- In April, the firm was awarded an additional $14.7 million contract to scale the technology across the agency.
The development process: Elsa emerged from competing internal AI initiatives following recent cost-cutting measures.
- Initially, each FDA center was working on its own AI pilot program.
- After budget cuts in May, the AI pilot from the Center for Drug Evaluation and Research (CDER-GPT) was selected for agency-wide scaling and rebranded as Elsa.
What they’re saying: FDA Chief AI Officer Jeremy Walsh characterized the launch as transformative for the agency.
- “Today marks the dawn of the AI era at the FDA. With the release of Elsa, AI is no longer a distant promise but a dynamic force enhancing and optimizing the performance and potential of every employee,” Walsh stated.
Counterpoints: Staffers warn that the current version of Elsa is not ready for scientific applications.
- “Makary and DOGE think AI can replace staff and cut review times, but it decidedly cannot,” one employee told Stat news.
- FDA employees also noted the agency has failed to establish proper guardrails for the tool’s use, with one stating: “I’m not sure in their rush to get it out that anyone is thinking through policy and use.”
Technical challenges: Problems extend beyond Elsa to other AI initiatives within the agency.
- Staff at the Center for Devices and Radiological Health reported that their AI pilot, CDRH-GPT, is buggy and disconnected from both the internet and FDA’s internal systems.
- Users have encountered problems uploading documents and submitting questions to the system.
Recent Stories
DOE fusion roadmap targets 2030s commercial deployment as AI drives $9B investment
The Department of Energy has released a new roadmap targeting commercial-scale fusion power deployment by the mid-2030s, though the plan lacks specific funding commitments and relies on scientific breakthroughs that have eluded researchers for decades. The strategy emphasizes public-private partnerships and positions AI as both a research tool and motivation for developing fusion energy to meet data centers' growing electricity demands. The big picture: The DOE's roadmap aims to "deliver the public infrastructure that supports the fusion private sector scale up in the 2030s," but acknowledges it cannot commit to specific funding levels and remains subject to Congressional appropriations. Why...
Oct 17, 2025Tying it all together: Credo’s purple cables power the $4B AI data center boom
Credo, a Silicon Valley semiconductor company specializing in data center cables and chips, has seen its stock price more than double this year to $143.61, following a 245% surge in 2024. The company's signature purple cables, which cost between $300-$500 each, have become essential infrastructure for AI data centers, positioning Credo to capitalize on the trillion-dollar AI infrastructure expansion as hyperscalers like Amazon, Microsoft, and Elon Musk's xAI rapidly build out massive computing facilities. What you should know: Credo's active electrical cables (AECs) are becoming indispensable for connecting the massive GPU clusters required for AI training and inference. The company...
Oct 17, 2025Vatican launches Latin American AI network for human development
The Vatican hosted a two-day conference bringing together 50 global experts to explore how artificial intelligence can advance peace, social justice, and human development. The event launched the Latin American AI Network for Integral Human Development and established principles for ethical AI governance that prioritize human dignity over technological advancement. What you should know: The Pontifical Academy of Social Sciences, the Vatican's research body for social issues, organized the "Digital Rerum Novarum" conference on October 16-17, combining academic research with practical AI applications. Participants included leading experts from MIT, Microsoft, Columbia University, the UN, and major European institutions. The conference...